News Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-06-12 EDT			5-day change	1st Jan Change
288.5 ^TWD	+0.35%		+0.35%	+6.07%

06-06	Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	CI
05-11	Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	06-05	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	03-26	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	01-31	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01-14	CI
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth	01-11	AQ
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth	23-10-12	AQ
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.	23-09-24	CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes	23-09-04	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	23-08-15	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia	23-08-10	BU
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA	23-08-02	AQ
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	23-07-31	CI
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	23-07-12	AQ
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	23-07-11	MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson	23-07-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

Summary

Filters